Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Emil Billbäck appointed new Chair of the Board of Intervacc
Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac® registered in 16 European countries, today announces that Chairman of the Board Håkan Björklund has handed over to Emil Billbäck, previously a Board member, who was elected as...Report from Annual General Meeting in Intervacc
Intervacc AB (publ) held its Annual General Meeting (”AGM”) on Wednesday 13 May 2026, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted the Board of Directors’ submitted income statement and balance sheet...Interim report January – March 2026
The Group in summary 01/01/26 01/01/25 01/01/25 -31/03/26 -31/03/25 -31/12/25 Net sales 3 374 4 574 20 087 Operating result -22 228 -13 537 -83 501 Result after financial items -21 724 -13...Intervacc strengthens management team for future growth
Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac® registered on 16 European markets, today announces that the company is strengthening its management team through the recruitment of Lars Stubberud as Chief Technology Officer...International Awareness Initiative Against Strangles
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, highlights the annual initiative Strangles Awareness Week – an international awareness campaign aimed at reducing the spread of strangles within the equine industry. In Sweden, the campaign...Nyhetstjänster
